All In Biotech

Drug Trial Radar · NCT02302807

A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]

A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer After Failure With Platinum-Containing Chemotherapy

Last checked: Nov 19, 2026Latest source record: Aug 1, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 931 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

931

Actual

Start

Jan 13, 2015

Primary completion

Mar 13, 2017

Study completion Nov 8, 2018

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Nov 27, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase III, global, multicenter, open-label, two-arm, randomized, controlled study designed to evaluate the efficacy and safety of atezolizumab compared with chemotherapy in participants with locally advanced or metastatic urothelial bladder cancer (UBC) who have progressed during or following a platinum-containing regimen. The anticipated time on study treatment is based on continued clinical benefit, i.e., until disease progression or unacceptable toxicity. The target sample size is 931 participants.

Conditions

  • Bladder Cancer

Interventions

  • Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibodyDrug

    Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on Day 1 of each 21-day cycle.

  • DocetaxelDrug

    Docetaxel 75 mg/m\^2 will be administered intravenously on Day 1 of each 21-day cycle.

  • PaclitaxelDrug

    Paclitaxel 175 mg/m\^2 will be administered intravenously on Day 1 of each 21-day cycle.

  • VinflunineDrug

    Vinflunine 320 mg/m\^2 will be administered intravenously on Day 1 of each 21-day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: Between randomization and death due to any cause, up to approximately 25 months after first participant enrolled

Locations

217 sites in 29 countries. Site status is shown where the registry gives one.

  • Georgetown University Medical Center Lombardi Cancer Center

    Washington D.C., District of Columbia

  • Emory University; Winship Cancer Institute

    Atlanta, Georgia

  • Comprehensive Cancer Centers of Nevada

    Las Vegas, Nevada

  • Duke Cancer Center

    Durham, North Carolina

  • Bon Secours - St. Francis Hospital

    Greenville, South Carolina

  • Vanderbilt-Ingram Cancer Ctr

    Nashville, Tennessee

  • Royal Brisbane and Women's Hospital; Medical Oncology

    Herston, Queensland, Australia

  • Royal Adelaide Hospital; Oncology

    Adelaide, South Australia, Australia

  • Monash Medical Centre; Oncology

    Clayton, Victoria, Australia

  • Austin and Repatriation Medical Centre; Cancer Services

    Melbourne, Victoria, Australia

  • Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Abt. für Onkologie

    Vienna, Austria

  • Kaiser-Franz-Josef-Spital; Zent.Onkologie und Hamatologie

    Vienna, Austria

  • ZNA Middelheim

    Antwerp, Belgium

  • Institut Jules Bordet

    Brussels, Belgium

  • UZ Gent

    Ghent, Belgium

  • UZ Leuven Gasthuisberg

    Leuven, Belgium

  • Tom Baker Cancer Centre-Calgary

    Calgary, Alberta, Canada

  • Bcca - Cancer Center Southern Interior

    Kelowna, British Columbia, Canada

  • BCCA-Vancouver Cancer Centre

    Vancouver, British Columbia, Canada

  • Bcca - Vancouver Island Cancer Centre; Oncology

    Victoria, British Columbia, Canada

  • Royal Victoria Hospital

    Barrie, Ontario, Canada

  • London Regional Cancer Centre

    London, Ontario, Canada

  • Lakeridge Health Oshawa; Oncology

    Oshawa, Ontario, Canada

  • The Ottawa Hospital Cancer Centre; Oncology

    Ottawa, Ontario, Canada

  • Sault Area Hospitals

    Sault Ste. Marie, Ontario, Canada

  • Sunnybrook Odette Cancer Centre

    Toronto, Ontario, Canada

  • McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology

    Montreal, Quebec, Canada

  • Masarykuv onkologicky ustav

    Brno, Czechia

  • Fakultni nemocnice Olomouc

    Olomouc, Czechia

  • MULTISCAN, s.r.o., Radiologicke centrum Pardubice

    Pardubice, Czechia

  • Fakultni nemocnice Kralovske Vinohrady

    Prague, Czechia

  • Vseobecna fakultni nemocnice v Praze

    Prague, Czechia

  • Herlev Hospital; Onkologisk afdeling

    Herlev, Denmark

  • Rigshospitalet; Onkologisk Klinik

    København Ø, Denmark

  • Docrates Cance Center

    Helsinki, Finland

  • Turku University Central Hospital; Urology clinic

    Turku, Finland

  • Ico - Paul Papin

    Angers, France

  • Institut Sainte Catherine;Recherche Clinique

    Avignon, France

  • Chr De Besancon - Hopital Jean Minjoz

    Besançon, France

  • Hopital Saint Andre

    Bordeaux, France

Showing 40 of 217 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.